




RealRate

PHARMACEUTICAL 2018

Enveric Biosciences Inc
Rank 210 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Enveric Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Enveric Biosciences Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 118% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 41% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	14,645
Cost of Goods Sold	38,356
Intangible Assets	31,368
Liabilities, Current	30,368
Liabilities, Non-Current	2,381
Other Assets	6,089
Other Compr. Net Income	-2,045
Other Expenses	1,307
Other Liabilities	0
Other Net Income	504
Other Revenues	48,594
Property and Equipment	95
Research and Development	0
Selling, General and Administrative Expense	18,510

Output Variable	Value in 1000 USD
Assets	52,197
Liabilities	32,748
Expenses	58,173
Revenues	48,594
Stockholders Equity	19,448
Net Income	-9,075
Comprehensive Net Income	-10,097
BaseVar	97,130
ECR before LimitedLiability	76%
Economic Capital Ratio	211%